Learn About Diabetic Macular Edema (DME)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Retina Group Of New York
James Maisel is an Ophthalmologist in Hicksville, New York. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Artery Occlusion, Cataract Removal, and Vitrectomy.
Stony Brook Internists University Faculty Practice Corporation
David Goodrich is an Internal Medicine provider in East Setauket, New York. Dr. Goodrich and is rated as an Experienced provider by MediFind in the treatment of Diabetic Macular Edema (DME). His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Familial Hypertension, Hypertension, and Glucocorticoid-Remediable Aldosteronism.
New York University
Nitish Mehta is an Ophthalmologist in Huntington Station, New York. Dr. Mehta and is rated as an Advanced provider by MediFind in the treatment of Diabetic Macular Edema (DME). His top areas of expertise are Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, and Vitrectomy.
Summary: The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications ...
Summary: This is a multicenter, randomized, parallel study to evaluate the efficacy and safety of two doses of ENN0403 in subjects with diabetic macular edema (DME). Approximately 60 subjects will be randomized to receive ENN0403 capsule orally once a day at the low dose or high dose with a 1:1 ratio. The study period consisted of up to 2 weeks of screening, 12 weeks of treatment and 2 weeks of follow-up, ...